Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells
LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc., a subsidiary of Immix Biopharma,…
Vocalbeats.AI Achieves ISO/IEC 42001 Certification, Reinforcing Responsible AI Governance